Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population

Microbes and Infection

Volumn 18, Issue 1, 2016, Pages 30-38

  Gu, Silan ^a   Chen, Yunbo ^a   Zhang, Xuewu ^b   Lu, Haifeng ^a   Lv, Tao ^a   Shen, Ping ^a   Lv, Longxian ^a   Zheng, Beiwen ^a   Jiang, Xiawei ^a   Li, Lanjuan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

16S rRNA gene sequence; Clostridium difficile infection; Intestinal microbiota

Indexed keywords

BUTYRIC ACID; RNA 16S; BACTERIAL DNA; RIBOSOME DNA;

ACTINOBACTERIA; ADULT; ANAEROBIC BACTERIUM; ARTICLE; BACTERIAL COLONIZATION; BACTEROIDETES; CHINA; CHINESE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; FECES MICROFLORA; FEMALE; FIRMICUTES; HIGH THROUGHPUT SEQUENCING; HUMAN; INFANT; INTESTINE; INTESTINE FLORA; MALE; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; PROTEOBACTERIA; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMISTRY; CLOSTRIDIUM INFECTION; DNA SEQUENCE; GENETICS; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; MIDDLE AGED; MOLECULAR GENETICS; ORGANISMAL INTERACTION;

ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DNA, BACTERIAL; DNA, RIBOSOMAL; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; MICROBIAL INTERACTIONS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, DNA;

EID: 84953837329     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2015.09.008     Document Type: Article

References (41)

1. Waaij V. The ecology of the human intestine and its consequences for overgrowth by pathogens such as Clostridium difficile. Annu Rev Microbiol 1989, 43(1):69-87.
2. van Vliet M.J., Tissing W.J., Dun C.A., Meessen N.E., Kamps W.A., de Bont E.S., et al. Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin Infect Dis 2009, 49(2):262-270.
3. Dubberke E.R., Olsen M.A. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012, 55(Suppl. 2):S88-S92.
4. Health U.D.o., Services H. Antibiotic resistance threats in the United States, 2013 2013, CDC, Atlanta.
5. Bartlett J.G. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008, 46(Supplement 1):S4-S11.
6. Ananthakrishnan A.N. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011, 8(1):17-26.
7. Clements A.C., Magalhães R.J., Tatem A.J., Paterson D.L., Riley T.V. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010, 10(6):395-404.
8. Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents 2009, 33:S33-S36.
9. Bakken J.S. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009, 15(6):285-289.
10. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011, 53(10):994-1002.
11. Borody T.J., Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 2012, 9(2):88-96.
12. Lawley T.D., Clare S., Walker A.W., Stares M.D., Connor T.R., Raisen C., et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012, 8(10):e1002995.
13. Reeves A.E., Koenigsknecht M.J., Bergin I.L., Young V.B. Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect Immun 2012, 80(11):3786-3794.
14. Nagaro K.J., Phillips S.T., Cheknis A.K., Sambol S.P., Zukowski W.E., Johnson S., et al. Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile. Antimicrob Agents Chemother 2013, 57(11):5266-5270.
15. Pérez-Cobas A.E., Artacho A., Ott S.J., Moya A., Gosalbes M.J., Latorre A. Structural and functional changes in the gut microbiota associated to Clostridium difficile infection. Front Microbiol 2014, 5.
16. Ling Z., Liu X., Jia X., Cheng Y., Luo Y., Yuan L., et al. Impacts of infection with different toxigenic Clostridium difficile strains on faecal microbiota in children. Sci Rep 2014, 4.
17. Chen Y.B., Gu S.L., Wei Z.Q., Shen P., Kong H.S., Yang Q., et al. Molecular epidemiology of Clostridium difficile in a tertiary hospital of China. J Med Microbiol 2014, 63(Pt 4):562-569.
18. Kato H., Kita H., Karasawa T., Maegawa T., Koino Y., Takakuwa H., et al. Colonisation and transmission of Clostridium difficile in healthy individuals examined by PCR ribotyping and pulsed-field gel electrophoresis. J Med Microbiol 2001, 50(8):720-727.
19. Muyzer G., De Waal E.C., Uitterlinden A.G. Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. Appl Environ Microbiol 1993, 59(3):695-700.
20. Magoč T., Salzberg S.L. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 2011, 27(21):2957-2963.
21. Edgar R.C. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods 2013, 10(10):996-998.
22. Edgar R.C., Haas B.J., Clemente J.C., Quince C., Knight R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 2011, 27(16):2194-2200.
23. Wang Q., Garrity G.M., Tiedje J.M., Cole J.R. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 2007, 73(16):5261-5267.
24. Dabney A., Storey J., Warnes G. Qvalue: Q-value estimation for false discovery rate control. R Package Version 1.26.0 2011.
25. Lu H., Wu Z., Xu W., Yang J., Chen Y., Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Microb Ecol 2011, 61(3):693-703.
26. Chen X., Lamont J.T. Overview of Clostridium difficile infection: implications for China. Gastroenterol Rep 2013, got029.
27. Hamilton M.J., Weingarden A.R., Unno T., Khoruts A., Sadowsky M.J. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 2013, 4(2):125-135.
28. Canani R.B., Costanzo M.D., Leone L., Pedata M., Meli R., Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011, 17(12):1519-1528.
29. Louis P., Flint H.J. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 2009, 294(1):1-8.
30. Gustafsson A., Lund-Tønnesen S., Berstad A., Midtvedt T., Norin E. Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment. Scand J Gastroenterol 1998, 33(7):721-727.
31. Antharam V.C., Li E.C., Ishmael A., Sharma A., Mai V., Rand K.H., Wang G.P. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol 2013, 51(9):2884-2892.
32. Banerjee P., Merkel G.J., Bhunia A.K. Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells. Gut Pathog 2009, 1(1):8.
33. Allen S.J., Wareham K., Wang D., Bradley C., Hutchings H., Harris W., et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013, 382(9900):1249-1257.
34. Hold G.L., Schwiertz A., Aminov R.I., Blaut M., Flint H.J. Oligonucleotide probes that detect quantitatively significant groups of butyrate-producing bacteria in human feces. Appl Environ Microbiol 2003, 69(7):4320-4324.
35. Sokol H., Pigneur B., Watterlot L., Lakhdari O., Bermúdez-Humarán L.G., Gratadoux J.J., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci 2008, 105(43):16731-16736.
36. Manges A.R., Labbe A., Loo V.G., Atherton J.K., Behr M.A., Masson L., et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridium difficile-associated disease. J Infect Dis 2010, 202(12):1877-1884.
37. Rousseau C., Levenez F., Fouqueray C., Doré J., Collignon A., Lepage P. Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition. J Clin Microbiol 2011, 49(3):858-865.
38. Schubert A.M., Rogers M.A., Ring C., Mogle J., Petrosino J.P., Young V.B., et al. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. MBio 2014, 5(3). e01021-14.
39. Bartlett J.G., Onderdonk A.B., Cisneros R.L., Kasper D.L. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 1977, 136(5):701-705.
40. Hopkins M., Macfarlane G. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 2002, 51(5):448-454.
41. Lupp C., Robertson M.L., Wickham M.E., Sekirov I., Champion O.L., Gaynor E.C., et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007, 2(2):119-129.